Leukocyte immunoglobulin-like receptor
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 6: | Line 6: | ||
*'''LILRA5''' has a role in triggering innate immune responses. | *'''LILRA5''' has a role in triggering innate immune responses. | ||
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>. | *'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>. | ||
| + | *'''LILRB3''' is a target for treatment against acute myeloid leukaemia<ref>PMID:38098451</ref>. | ||
| + | *'''LILRB4''' suppresses immunity in solid tumors<ref>PMID:33974041</ref>. | ||
See also: | See also: | ||
| Line 19: | Line 21: | ||
*LILR; ligand-binding domain D1D2 27-221; ligand-binding domain D3D4 222-417 | *LILR; ligand-binding domain D1D2 27-221; ligand-binding domain D3D4 222-417 | ||
| - | * | + | *LILR subfamily A member 2 |
**[[2otp]] – hLILRA2 ligand-binding domain D1D2 - human<br /> | **[[2otp]] – hLILRA2 ligand-binding domain D1D2 - human<br /> | ||
| - | * | + | *LILR subfamily A member 3 |
**[[3q2c]] – hLILRA3 N-terminal domain <br /> | **[[3q2c]] – hLILRA3 N-terminal domain <br /> | ||
| - | * | + | *LILR subfamily A member 5 |
**[[2d3v]] – hLILRA5 extracerllular domain <br /> | **[[2d3v]] – hLILRA5 extracerllular domain <br /> | ||
**[[1vdg]] – hLILRA5 ligand-binding domain D1D2 (mutant) <br /> | **[[1vdg]] – hLILRA5 ligand-binding domain D1D2 (mutant) <br /> | ||
| - | * | + | *LILR subfamily A member 6 |
| + | |||
| + | **[[8grx]] – hLILRA6 extracerllular domain + apolipoprotein B – Cryo EM <br /> | ||
| + | |||
| + | *LILR subfamily B member 1 | ||
**[[1g0x]] – hLILRB1 ligand-binding domain D1D2<br /> | **[[1g0x]] – hLILRB1 ligand-binding domain D1D2<br /> | ||
| Line 43: | Line 49: | ||
**[[3d2u]] – hLILRB1 ligand-binding domain D1D2 + herpesvirus UL18 + β-2 microglobulin + actin peptide<br /> | **[[3d2u]] – hLILRB1 ligand-binding domain D1D2 + herpesvirus UL18 + β-2 microglobulin + actin peptide<br /> | ||
| - | * | + | *LILR subfamily B member 2 |
**[[4lla]] – hLILRB2 ligand-binding domain D3D4 <br /> | **[[4lla]] – hLILRB2 ligand-binding domain D3D4 <br /> | ||
| Line 49: | Line 55: | ||
**[[2gw5]] – hLILRB2 ligand-binding domain D1D2 <br /> | **[[2gw5]] – hLILRB2 ligand-binding domain D1D2 <br /> | ||
**[[6bcs]] – hLILRB2 ligand-binding domain D1D2 + benzamidine<br /> | **[[6bcs]] – hLILRB2 ligand-binding domain D1D2 + benzamidine<br /> | ||
| + | **[[9c9c]] – hLILRB2 ligand-binding domain D1D2 + imidazole<br /> | ||
| + | **[[9c9d]] – hLILRB2 ligand-binding domain D1D2 + MHC + beta-2-microglobulin + T cell receptor + pteridin<br /> | ||
**[[2dyp]] – hLILRB2 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin + H2A peptide<br /> | **[[2dyp]] – hLILRB2 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin + H2A peptide<br /> | ||
| - | * | + | *LILR subfamily B member 3 |
**[[6grq]], [[6grs]], [[6grt]] – mLILRB3 extracellular domain 25-619 <br /> | **[[6grq]], [[6grs]], [[6grt]] – mLILRB3 extracellular domain 25-619 <br /> | ||
| - | * | + | *LILR subfamily B member 4 |
**[[3p2t]] – hLILRB4 ligand-binding domain D1D2 <br /> | **[[3p2t]] – hLILRB4 ligand-binding domain D1D2 <br /> | ||
Current revision
| |||||||||||
3D structures of leukocyte immunoglobulin-like receptor
Updated on 26-October-2025
References
- ↑ Thomas R, Matthias T, Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):159-62. doi:, 10.1007/s12016-009-8148-8. PMID:19548123 doi:http://dx.doi.org/10.1007/s12016-009-8148-8
- ↑ Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023 Sep 13;14:1240275. PMID:37781391 doi:10.3389/fimmu.2023.1240275
- ↑ Mai S, Hodges A, Chen HM, Zhang J, Wang YL, Liu Y, Nakatsu F, Wang X, Fang J, Xu Y, Davidov V, Kang K, Pingali SR, Ganguly S, Suzuki M, Konopleva M, Prinzing B, Zu Y, Gottschalk S, Lu Y, Chen SH, Pan PY. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 Dec 15;83(24):4047-4062. PMID:38098451 doi:10.1158/0008-5472.CAN-22-2483
- ↑ Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 Jul 5;218(7):e20201811. PMID:33974041 doi:10.1084/jem.20201811
